

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



韋俊生物科技有限公司
Wai Chun Bio-Technology Limited
(Incorporated in Cayman Islands with limited liabilities)
(Stock code : 0660)

**RESIGNATION OF CHIEF FINANCIAL OFFICER, COMPANY SECRETARY
AND AUTHORISED REPRESENTATIVE**

The board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”) announces that, with effect from 10 May 2021, Dr. Ng Chun Pang (“**Dr. Ng**”) resigned as the Chief Financial Officer, Company Secretary and Authorised Representative of the Company as Dr. Ng would like to devote more time for his personal future development.

Dr. Ng has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that should be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

The Company is in the process of identifying a suitable candidate to fill the vacancy of Chief Financial Officer, Company Secretary and Authorised Representative caused by the resignation of Dr. Ng, and will publish further announcement once such appointment is confirmed.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ching Kui
Chairman and Chief Executive Officer

Hong Kong, 10 May 2021

As at the date of this announcement, the Board comprises:

Executive Director:

LAM Ching Kui (Chairman and Chief Executive Officer)

Independent Non-executive Directors:

CHAN Cheuk Ho

WAN Bo

HAU Pak Man